Loading provider…
Loading provider…
Hematology & Oncology Physician in La Jolla, CA
NPI: 1417120080Primary Practice Location
SCRIPPS GREEN HOSPITAL
10666 N Torrey Pines Rd, La Jolla, CA
Primary Employer
Scripps Clinic
scripps.org
HQ Phone
Get MD Darren's Phone Numberphone_androidMobile
Get MD Darren's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
IL State Medical License
2024 - 2026
CA State Medical License
2003 - 2025

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
David Geffen School of Medicine at UCLA
medschool.ucla.edu
Medical School
Until 2002
Scripps Clinic/Scripps Green Hospital
Fellowship • Hematology and Medical Oncology
2005 - 2008
University of California Davis Health
Residency • Internal Medicine
2002 - 2005
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 290 | 883 |
| 2 | 96413Infusion of chemotherapy into a vein up to 1 hour | 148 | 735 |
| 3 | 96375Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | 127 | 1,460 |
| 4 | 99215Established patient office or other outpatient, visit typically 40 minutes | 119 | 332 |
| 5 | J1626Injection, granisetron hydrochloride, 100 mcg | 110 | 5,740 |
Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors.
Authors: Vincent Miller, Munveer Bhangoo, Jonathan Hermel
Journal: Oncotarget
Publication Date: 2018-11-09
Hairy cell leukemia: current therapies and future directions
Authors: Alan Saven, Gregory Vosganian
Publication Date: 2010-12
Authors: Apostolia Tsimberidou, Heinz-Josef Lenz, Michael Saville
Journal: Cancer Chemother Pharmacol
Publication Date: 2024-09-23
Lead Sponsor: Celularity Incorporated
Intervention / Treatment: DRUG: Trastuzumab, DRUG: Pembrolizumab, DRUG: Cyclophosphamide, DRUG: Mesna, DRUG: Fludarabine, BIOLOGICAL: CYNK-101, DRUG: Recombinant Human Interleukin-2
Lead Sponsor: Aravive, Inc.
Intervention / Treatment: DRUG: Gemcitabine, DRUG: Nab paclitaxel, DRUG: batiraxcept
Lead Sponsor: Halozyme Therapeutics
Intervention / Treatment: DRUG: Atezolizumab, DRUG: PEGPH20, DRUG: CIS, DRUG: GEM